Pharmaceuticals

Global Vasodilators Market Performance Report: Global Trends 2026–2030

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the vasodilators market from 2026–2035 with trusted insights from The Business Research Company

How much is the Vasodilators Market valued at in 2026, and what valuation is forecast for 2030?

The vasodilators market size has experienced robust growth in recent years. This market is projected to expand from $6.76 billion in 2025 to $7.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.0%. Historically, this expansion has been driven by factors such as the increasing prevalence of hypertension, the established clinical application of nitrates, an expansion in hospital infrastructure, a rising occurrence of heart failure, and the widespread accessibility of oral vasodilators.

The vasodilators market is projected to experience robust expansion in the coming years, reaching a valuation of $8.86 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period stems from factors such as an aging worldwide population, the increasing prevalence of lifestyle-related ailments, the proliferation of specialized cardiac facilities, enhanced emphasis on timely diagnosis, and improved availability of cardiovascular drugs. Key trends expected to shape the market during this period involve the escalating incidence of cardiovascular diseases, the increasing application of combination drug treatments, wider acceptance of generic vasodilators, the expansion of cardiovascular care provided in hospitals, and a greater need for sustained management of hypertension.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

What Drivers Are Influencing The Growth Of The Vasodilators Market?

The increasing occurrence of cardiovascular diseases is projected to fuel the expansion of the vasodilators market moving forward. These diseases are a category of conditions affecting the heart and blood vessels, including issues like coronary artery disease, heart failure, and stroke. The growing incidence of cardiovascular diseases is influenced by increasing obesity rates, which continue to climb due to poor dietary quality and inactive lifestyles. The vasodilators market assists in managing cardiovascular diseases by inducing relaxation in blood vessels, lowering blood pressure, and enhancing overall blood circulation. For instance, in January 2024, data from the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, showing a 4.0% rise from 224.4 per 100,000 in 2023. Hence, the increasing prevalence of cardiovascular diseases is propelling the growth of the vasodilators market.

How Is The Vasodilators Market Organized Into Various Segments?

The vasodilators market covered in this report is segmented –

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators

2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs

3) By Indication: Hypertension, Angina, Heart Failure, Other Indications

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators

2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors)

3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

Which Trends Are Guiding The Evolution Of The Vasodilators Market?

Leading companies within the vasodilators market are increasingly concentrating on the creation of innovative solutions, such as inhaled soluble guanylate cyclase (sGC) activators, designed to enhance pulmonary blood flow and more effectively manage cardiovascular conditions. These inhaled soluble guanylate cyclase (sGC) activators are medications that, upon inhalation, stimulate the sGC enzyme, leading to blood vessel relaxation and improved blood circulation, particularly in the lungs. For instance, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology firm, launched mosliciguat, a once-daily, inhaled sGC activator delivered via a dry powder inhaler (DPI), developed by its subsidiary Pulmovant. Mosliciguat is specifically formulated for lung-targeted delivery, activating sGC independently of heme and NO, which may help preserve its function even under oxidative stress. A Phase 1b “ATMOS” study demonstrated mean-max reductions in pulmonary vascular resistance (PVR) of up to ~38% in pulmonary hypertension patients. The product was generally well tolerated, with minimal adverse events, and its pharmacokinetic profile supports a once-daily inhalation due to a long half-life and limited systemic exposure. Pulmovant has now initiated a global Phase 2 “PHocus” trial involving approximately 120 patients with PH-ILD to further evaluate its safety and efficacy.

Who Are The Core Companies Influencing Trends In The Vasodilators Market?

Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Which Regions Are Projected To Dominate The Vasodilators Market In The Coming Years?

North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Vasodilators Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16565&type=smp

Browse Through More Reports Similar to the Global Vasodilators Market 2026, By The Business Research Company

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Peripheral Vasodilator Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795